Beta Drugs Limited
NSE: BETA · Other · sector
₹1,977.90NSE close 2026-10-26
Key numbers
Market cap₹2,200 cr
Price₹1,977.90
52w high / low₹2,808 / ₹990
P/E40.6xSector median 14.4x
P/B5.0xSector median 1.7x
Book value₹393.6
Dividend yield–Sector median 0.37%
ROE16.4%Sector median 13.8%
ROCE17.0%Sector median 19.6%
OPM20.8%Sector median 10.4%
Debt / equity0.11xSector median 0.29x
EV/EBITDA23.2xSector median 8.4x
Interest cover6.6x
Current ratio2.63x
Sales growth 3y–Sector median +7.7%
Profit growth 3y–Sector median +16.6%
PEG–
Last 12 months to Sep 2026, Consolidated. "Sector median" = middle value of 688 companies in Other (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹125 cr vs borrowings ₹148 cr (FY26): borrowings are higher by ₹23 cr.
- Operating profit covered interest 6.6x in the last 12 months.
- Promoter holding fell by 7.82 percentage points in a year, to 58.91% (2026-09-30).
- Other income was 16% of net profit in the last 12 months.
- No dividend in the last 2 financial years.
- Price ₹1,977.90 on 2026-10-26: -29.6% from the 52-week high, +99.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,559.00 · low ₹1,051.60
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Revenue | 182 | 204 | 87 | 94 | 126 | 137 |
| EBITDA | 31 | 41 | 17 | 18 | 27 | 30 |
| OPM % | 17.2% | 20.1% | 19.5% | 18.8% | 21.8% | 22.0% |
| Other income | 5 | 6 | 2 | 3 | 2 | 2 |
| Net profit | 18 | 24 | 9 | 9 | 16 | 19 |
| EPS (₹) | 17.81 | 47.38 | 8.40 | 8.93 | 14.78 | 16.59 |
| Revenue YoY | -31.0% | -32.5% | ||||
| Profit YoY | -8.3% | -19.4% |
Consolidated figures where filed. Latest quarter Sep 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 362 | 385 | 444 |
| EBITDA | 70 | 76 | 92 |
| Net profit | 42 | 41 | 53 |
| EPS (₹) | 42.02 | 40.92 | 48.70 |
| Revenue growth | +6.2% | – | |
| Profit growth | -2.2% | – | |
| Dividend / share (₹) | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -4.0% (2y) | -8.6% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 187 | 245 |
| Borrowings | – | 148 |
| Cash & equivalents | 147 | 125 |
| Total assets | 436 | 496 |
| Fixed assets | 80 | 115 |
| Capital work in progress | – | 0 |
| Investments | 0 | 0 |
| Receivables | – | 119 |
| Inventory | 60 | 74 |
| Payables | – | 81 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 32 | 37 |
| Cash from investing | -36 | -51 |
| Cash from financing | 118 | -8 |
| Capex | 37 | 53 |
| Free cash flow | -5 | -16 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 22.7% | 16.9% |
| ROCE % | 34.2% | 17.8% |
| Debtor days | – | 113 |
| Inventory days | 127 | 159 |
| Payable days | – | 172 |
| Cash conversion cycle (days) | – | 100 |
| Working capital days | 230 | 215 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 58.91% |
| FIIs | 1.37% |
| DIIs | 6.45% |
| Public (non-institutions) | 33.27% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | May 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 66.73% | 66.73% | 66.73% | 64.90% | 64.63% | 59.10% | 59.10% | 58.91% |
| Promoter group | % |
|---|---|
| Neeraj Batra | 58.21% |
| Rahul Batra | 0.37% |
| Varun Batra | 0.31% |
| Heena Batra | 0.01% |
| Aditi Batra | 0.01% |
| Public holders above 1% | % |
|---|---|
| Suryavanshi Commotrade Private Limited | 6.11% |
| Ashish Kacholia | 4.43% |
| Healthquad Trust II | 4.28% |
| Inti Capital VCC - Inti Capital I | 2.00% |
| Airavat Capital Trust - Airavat Capital Trust II | 1.59% |
| Bsas Infotech Limited | 1.19% |
| Anjali Ajit Deval | 1.13% |
| Onkar Singh | 1.01% |
10,145 shareholders. Pledged: – of promoter shares.
Peers in Other
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| TSFINV | ₹8,585 cr | 17.6x | 1.4x | 8.4% | 3.6% | 20.5% | +121.7% | 2.30% |
| KRISHANA | ₹6,339 cr | 39.9x | 11.3x | 41.6% | 23.2% | 12.6% | +95.7% | 0.05% |
| MARINE | ₹5,431 cr | 84.2x | 11.0x | 14.3% | 18.0% | 10.8% | +25.6% | 0.07% |
| ZOTA | ₹4,139 cr | – | 6.0x | -22.5% | -12.4% | -0.5% | +56.7% | 0.07% |
| AIMTRON | ₹3,319 cr | 71.7x | 17.1x | 28.0% | 31.8% | 21.8% | – | – |
| ACCORD | ₹2,984 cr | – | 261.7x | 12.4% | 12.0% | 2.4% | – | – |
| MONOLITH | ₹2,646 cr | 64.6x | 24.3x | 36.0% | 48.7% | 24.4% | – | – |
| UTSSAV | ₹2,390 cr | 40.2x | 14.1x | 43.4% | 54.7% | 7.9% | – | – |
| BETA | ₹2,200 cr | 40.6x | 5.0x | 16.4% | 17.0% | 20.8% | – | – |
| SAKAR | ₹2,160 cr | 59.9x | 6.7x | 11.8% | 14.8% | 28.5% | +23.6% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | |
| Industry | Other |
| Sub-industry | |
| Symbol | BETA |
| BSE code | – |
| ISIN | INE351Y01019 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.